Program
humanized bispecific antibody neutralizing both sclerostin AND DICKKOPF-1 (AGA-2115)
Its studies are mostly in Osteogenesis Imperfecta, led by 2 companies.
Drug pageHumanized bispecific antibody neutralizing both sclerostin AND DICKKOPF-1 (AGA-2115): every studyAll 3 studies of it, academic ones too, with its approvals, label and forms.Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Angitiaits history only | 21 open or running | phase 2since Jul 1, 2025 | Oct 11, 2023 | Nov 2027phase 2 · NCT07062588 |
| Angitia Biopharmaceuticals Guangzhouits history only | 11 open or running | phase 2since Apr 23, 2026 | Apr 23, 2026 | Apr 2028phase 2 · NCT07557446 |
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and studies of every company. Pick one to see its own:
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Oct 11, 2023First study: phase 1 study in Osteogenesis ImperfectaNew to AngitiaAngitia · NCT06086613 · 72 enrolled · United States
- Jul 1, 2025Phase 2 study in Osteogenesis ImperfectaAngitia · NCT07062588 · 80 planned · United States, Argentina, Australia and more
- Apr 23, 2026Angitia Biopharmaceuticals Guangzhou’s first study: phase 2 study in Osteogenesis ImperfectaNew to Angitia Biopharmaceuticals GuangzhouAngitia Biopharmaceuticals Guangzhou · NCT07557446 · 48 planned · China
Ahead
- Nov 2027Primary completion: phase 2 study in Osteogenesis ImperfectaAngitia · NCT07062588
- Apr 2028Primary completion: phase 2 study in Osteogenesis ImperfectaAngitia Biopharmaceuticals Guangzhou · NCT07557446
TargetBeta
Not stated by its company or a source we have read. Most early programs say nothing of it.
Studies
All 3 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Led by | Primary completion | Size |
|---|---|---|---|---|---|
| NCT07557446Osteogenesis Imperfecta · China | 2 | Recruiting | Angitia Biopharmaceuticals Guangzhou | Apr 2028 | 48 |
| NCT07062588Osteogenesis Imperfecta · United States, Argentina, Australia and more | 2 | Recruiting | Angitia | Nov 2027 | 80 |
| NCT06086613Osteogenesis Imperfecta · United States | 1 | Completed | Angitia | Oct 17, 2024 | 72 |
How it is read
Names in the registry
- “AGA2115”, 3 entries
Conditions, from the studies’ own filings
- Osteogenesis Imperfecta, 3 studies
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.